Final overall survival analysis for the phase II RECORD-3 study of first-line everolimus followed by sunitinib versus first-line sunitinib followed by everolimus in metastatic RCC.

Download full-text PDF	Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6290878	PMC
http://dx.doi.org/10.1093/annonc/mdx807	DOI Listing

Publication Analysis

final survival

survival analysis

analysis phase

phase record-3

record-3 study

study first-line

first-line everolimus

everolimus sunitinib

sunitinib versus

versus first-line

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!